Rohto Pharmaceutical Co., Ltd. operates within the Pharmaceutical preparations sector.
In addition to historical fundamental analyses, the complete report available to purchase compares Rohto Pharmaceutical Co., Ltd. with three other
companies in this sector in JAPAN :
Nichi-Iko Pharmaceutical Company Limited
sales of 190.08 billion Japanese Yen [US$1.81 billion]
of which 82%
was Nichiiko Group),
Sawai Pharmaceutical Co., Ltd.
(182.54 billion Japanese Yen [US$1.74 billion]
of which 79%
was Japan), and
Santen Pharmaceutical Company Limited
(241.56 billion Japanese Yen [US$2.30 billion]
of which 93%
was Pharmaceuticals Products).
During the year ended March of 2020, sales at
Rohto Pharmaceutical Co., Ltd. were ¥188.33 billion (US$1.79 billion).
increase of 2.6%
versus 2019, when the company's sales were ¥183.58 billion.
This was the third consecutive year of growth at Rohto Pharmaceutical Co., Ltd..
Sales of Operating Segment-Japan saw an increase
3.2% in 2020, from
¥112.17 billion to ¥115.77 billion.
Not all segments of Rohto Pharmaceutical Co., Ltd. experienced an increase in sales in 2020:
sales of Operating Segment-Other fell 9.3% to ¥1.73 billion.
(However, this segment's sales were only a very small portion of the company's overall sales).
Rohto Pharmaceutical Co., Ltd. also experienced decreases in sales in
Operating Segment-America (down 1.9% to ¥9.12 billion)